Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > October 3, 2022
Daily News
October 3, 2022
- MHLW Panel Proposes Lifting Bans on Cannabis-Derived Drugs, Introducing Distribution Control
October 3, 2022
- Celltrion Aims to Market 11 Biosimilars in Japan, Infliximab “Biobetter” in the List
October 3, 2022
- Novartis Ordered to Pay US$177.8 Million to Daiichi Sankyo over Patent Row
October 3, 2022
- Rohto Begins PIIb Dry Eye Study for JAK Drug Delgocitinib in Japan
October 3, 2022
- EMA Accepts Astellas’ Hot Flash Drug for Review
October 3, 2022
- Sanofi Seeks Japan Nod for Once-Weekly Hemophilia Med
October 3, 2022
- Ivermectin Fails in Investigator-Led COVID Trial Too
October 3, 2022
- Japan Ends Supply of AstraZeneca’s COVID Jab, 13.5 Million Doses Discarded
October 3, 2022
- PMDA Will “Appropriately Review” Lecanemab If Filed: Minister
October 3, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…